RxSight, Inc. (NASDAQ:RXST) Stock Position Raised by Paragon Advisors LLC

Paragon Advisors LLC grew its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 3.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,399 shares of the company’s stock after acquiring an additional 935 shares during the period. Paragon Advisors LLC owned 0.08% of RxSight worth $1,552,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. acquired a new position in shares of RxSight during the first quarter valued at about $364,000. Swiss National Bank raised its position in RxSight by 16.2% in the 1st quarter. Swiss National Bank now owns 53,100 shares of the company’s stock worth $2,739,000 after purchasing an additional 7,400 shares during the last quarter. ProShare Advisors LLC bought a new position in RxSight in the first quarter valued at about $263,000. M&G Plc acquired a new stake in shares of RxSight during the 1st quarter worth approximately $7,354,000. Finally, Vanguard Group Inc. raised its position in shares of RxSight by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after acquiring an additional 40,500 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $45.05 on Friday. The company has a market capitalization of $1.82 billion, a PE ratio of -54.28 and a beta of 1.19. RxSight, Inc. has a 1 year low of $27.07 and a 1 year high of $66.54. The business has a fifty day moving average price of $50.32 and a two-hundred day moving average price of $53.27.

Insiders Place Their Bets

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $2,225,096.82. This represents a 6.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jesse Anderson Corley acquired 11,111 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the transaction, the director now owns 468,571 shares in the company, valued at approximately $21,259,066.27. This represents a 2.43 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 44,745 shares of company stock worth $2,240,200 over the last quarter. 9.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RXST shares. Oppenheimer lowered their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group started coverage on RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Stifel Nicolaus dropped their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight currently has a consensus rating of “Buy” and a consensus target price of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.